Human C-Peptide ELISA kit

CAT#: EA100869

Human C-Peptide ELISA kit

Specifications

Product Data

• Format: 8x12 divisible strips
• Assay Type: Solid Phase Sandwich ELISA
• Assay Length: 3 hours
• Signal: Colorimetric
• Curve Range: 0.2-10 ng/ml
• Sample Type: Serum
• Sample Volume: 50µl/well
• Specificity: This kit is used for quantitative detection human C-Peptide
• Sensitivity: 0.2 ng/ml
• Reactivities: Human
• Cross Reactivity: There is no detectable cross-reactivity with other relevant proteins.
• Interference: No significant interference observed with available related molecules.
• Components:
  • Microwells coated with Streptavidin Ab: 12x8x1
  • Standards (1-6) 6 vials, lyophylized: Reconstitute with 1 ml DH2O
  • C-peptide Conjugate Reagent (Ready to use): 12 ml
  • TMB Solution: 12 ml
  • Stop Solution: 12 ml
  • Wash Solution 20X: 25 ml
• Background: Human C-Peptide has a molecular mass of approximately 3000 daltons. C-Peptide has no metabolic function. However, since C-Peptide and insulin are secreted in equimolar amounts, the immunoassay of C-Peptide permits the quantitation of insulin secretion. This is the reason for the clinical interest of serum or plasma determinations of C- Peptide. Moreover, C-Peptide measurement has several advantages over immunoassays of insulin. The half-life of C- Peptide in the circulation is between two and five times longer than that of insulin. Therefore, C-Peptide levels are a more stable indicator of insulin secretion than the more rapidly changing levels of insulin. A very clear practical advantage of C-Peptide measurement arising from its relative metabolic inertness as compared to insulin is that C- Peptide levels in peripheral venous blood are about 5-6 times greater than insulin levels. Also, relative to an insulin assay, the C-Peptide assay's advantage is its ability to distinguish endogenous from injected insulin. C-Peptide has also been measured as an additional means for evaluating glucose tolerance and glibenclamide glucose tests. C- Peptide levels are in many ways a better measurement of endogenous insulin secretion than peripheral insulin levels. C-Peptide may be measured in either blood or urine. With improved sensitive C-Peptide immunoassays, it is now possible to measure C-Peptide values at extremely low levels. The clinical indications for C-Peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy, and evaluation of viability of islet cell transplants. Recently, these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus